+

WO1992000080A1 - Procede de traitement de leucemies - Google Patents

Procede de traitement de leucemies Download PDF

Info

Publication number
WO1992000080A1
WO1992000080A1 PCT/US1991/004545 US9104545W WO9200080A1 WO 1992000080 A1 WO1992000080 A1 WO 1992000080A1 US 9104545 W US9104545 W US 9104545W WO 9200080 A1 WO9200080 A1 WO 9200080A1
Authority
WO
WIPO (PCT)
Prior art keywords
vector
rna molecule
ribozyme
abl
sequence
Prior art date
Application number
PCT/US1991/004545
Other languages
English (en)
Inventor
Premkumar Reddy
Scott Shore
Original Assignee
The Wistar Institute Of Anatomy & Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wistar Institute Of Anatomy & Biology filed Critical The Wistar Institute Of Anatomy & Biology
Priority to EP91912361A priority Critical patent/EP0639226A1/fr
Publication of WO1992000080A1 publication Critical patent/WO1992000080A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Definitions

  • This invention refers generally to the treatment of cancers, and more specifically to methods for treating leukemias characterized by the presence of a chimeric protein such as those produced by a genetic translocation.
  • Philadelphia chromosome is a hybrid chromosome resulting from a chromosomal translocation in which a small portion of the long arm of chromosome 9 is transferred to the long arm of chromosome 22.
  • This chromosomal abnormality consistently associates with human chronic myelogenous leukemia (CML) .
  • CML is a disorder of hematopoietic cells which results in marked proliferation of granulocytic cells and often megakaryocytes.
  • c-abl gene Philadelphia Chromosome, a portion of the c-abl gene is translocated from chromosome 9q34 to chromosome 22qll.
  • this translocation disrupts two genes, c-r_ abl of chromosome 9 and the ber gene of chromosome 22, resulting in the generation of a new, fused gene comprising portions of ber and c-abl.
  • BCR-ABL This chimeric gene, termed bcr-abl , produces a new protein, BCR-ABL which has several unique properties and appears to be the causative agent of the cancers with which it is associated (See Fig. 1) .
  • BCR-ABL protein is present only in tumor cells and its synthesis in these tumor cells is believed to be related to tumorigenicity.
  • CML and ALL patients are treated chemotherapeutically with conventional therapeutics and radiation. Such treatment is plagued by well-known side- effects and is often of limited effect. No effective treatment for these leukemias is known. Thus, other compositions and methods for treating such cancers are being sought.
  • RNA molecules possess the property of self-catalyzed cleavage. This reaction is shared by a number of small circular molecules which replicate in plants, either viroid RNAs, such as the avocado sunblotch viroid (ASBV) or satellite RNAs which are dependent on helper viruses, such as the satellite RNAs of tobacco ringpost virus and lucerne transient streak virus [Haseloff et al, Nature, 334:585-591 (1988)].
  • viroid RNAs such as the avocado sunblotch viroid (ASBV)
  • satellite RNAs which are dependent on helper viruses, such as the satellite RNAs of tobacco ringpost virus and lucerne transient streak virus [Haseloff et al, Nature, 334:585-591 (1988)].
  • hammerhead* 1 a consensus secondary structure, termed "hammerhead* 1 , containing Il ⁇ ls conserved nucleotides at the junction of three helices that are precisely positioned with respect to the cleavage site.
  • a hammerhead of less than 60 contiguous nucleotides was found to be sufficient for rapid cleavage in the absence of any protein [D.E. Ruffner et al, Gene. 82:31-41 (1989)].
  • Natural catalytic centers may be formed by contiguous regions in the RNA [P. Keese et al, in Viroids and Viroid-Like Pathogens , J.S. Semancik, ed.
  • RNA catalytic sequences require the conserved cleavage domain (GUX) to serve as the compatible substrates [Haseloff et al, supra] .
  • the present invention provides therapeutic compositions and methods for the treatment of leukemias, which are characterized by the presence of a chimeric protein which results from a chromosomal translocation.
  • the invention provides a composition comprising a synthetic RNA molecule, useful for the treatment of a leukemia characterized by the presence of a hybrid gene resulting from a chromosomal translocation coding for a protein which confers tumorigenicity to a human cell.
  • the synthetic molecule comprises a single strand of ribonucleic acids comprising a sequence complementary to a sequence of the coding strand of the hybrid gene 5' to the breakpoint of the translocation and capable of hybridizing thereto, a second sequence complementary to a sequence of the coding strand of the hybrid gene 3' to the breakpoint of the translocation and capable of hybridizing thereto, and a sequence therebetween encoding a ribozyme capable of cleaving the hybrid gene at or near the breakpoint.
  • the ribozyme sequence is preferably a hammerhead motif.
  • the invention provides a composition comprising a synthetic RNA molecule, useful for the treatment of CML characterized by the presence of the hybrid gene bcr-abl coding for the BCR-ABL protein which confers tumorigenicity to a human cell.
  • the synthetic RNA molecule comprises a single strand of ribonucleic acids comprising a sequence complementary to a sequence of the coding strand of the bcr-abl gene 5' to the breakpoint of the translocation and capable of hybridizing thereto, a second sequence complementary to a sequence of the coding strand of the hybrid gene 3• to the breakpoint of the translocation and capable of hybridizing thereto, and a sequence therebetween encoding a ribozyme capable of cleaving the hybrid chromosome at or near the breakpoint.
  • These molecules may be synthesized by conventional means, or expressed from a recombinant expression vector.
  • a further aspect of the present invention provides recombinant vectors carrying the synthetic RNA molecules described above.
  • Vectors of this invention are capable of expressing the RNA molecule and delivering the RNA molecule into a cell of a leukemic patient. These vectors are preferably recombinant retroviral vectors which have been altered to eliminate their pathogenicity. Other mammalian vectors may also be employed for this purpose which are capable of delivering the RNA molecule to the cell without otherwise damaging the cells.
  • Still another aspect of the present invention provides a method of treating leukemia with the above- described molecules and recombinant vectors.
  • This method entails contacting cells of a patient suffering from leukemia with an effective amount of the synthetic RNA molecule. Once in the cell, the synthetic RNA molecule binds repeatedly to copies of the hybrid gene and the ribozyme cleaves the gene in a catalytic manner, rendering it incapable of coding for the chimeric protein.
  • Fig. 1 illustrates the formation of Philadelphia Chromosome from a translocational event between chromosomes 9 and 22.
  • the translocation leads to the synthesis of a chimeric RNA message where 5* abl sequences are replaced by ber sequences producing an approximately 210 kilodalton hybrid BCR-ABL protein.
  • Fig. 2 illustrates the structure and sequence of one such synthetic ribozyme RNA molecule of this invention and the bcr-abl RNA substrate or "hammerhead" molecule. As is shown in Fig. 2, this RNA molecule is capable of forming duplexes with bcr-abl RNA.
  • Fig. 3 illustrates an autoradiogra demonstrating the effects of the RNA molecule on the bcr- abl gene transcript.
  • Lane 2 contains the 32 P labelled bcr-abl RNA transcript and MgCl 2 as a control; Lane 3 contains MgCl 2 and the unlabelled ribozyme as a control; Lane 4 contains EDTA and the labelled bcr-abl transcript as a control; Lanes 5 and 6 each contain MgCl 2 , the ribozyme molecule and the labeled bcr-abl transcript; Lane 7 contains EDTA, the ribozyme molecule and the labeled bcr-abl transcript as a control.
  • compositions and methods of the present invention are designed for the treatment of any leukemia or other cancer which is characterized by the presence of a tumorigenic chimeric protein such as that resulting from a chromosomal translocation, the gene encoding the protein having a ribozyme cleavage site at or near the chromosomal breakpoint.
  • a tumorigenic chimeric protein such as that resulting from a chromosomal translocation
  • the gene encoding the protein having a ribozyme cleavage site at or near the chromosomal breakpoint Exemplary disorders characterized by such a protein include chronic myelogenous leukemia, acute lymphocytic leukemia, as well as other leukemias, such as those involving c-myc 8q24 and bcl-1 and bcl-2.
  • the invention provides a synthetic RNA molecule or ribozyme.
  • the following description relates to a novel RNA molecule of this invention designed for the cleavage of the bcr-abl mRNA produced by the Philadelphia chromosome.
  • the present invention is not limited to this molecule, but encompasses other molecules designed according to this invention for cleavage of similar genes in other cancers.
  • the novel ribozyme has been designed to cleave the selected target chimeric gene after the ribonucleic acid sequence G-U-X, wherein X is the ribonucleo ides A, U or C.
  • a hammerhead ribozyme motif that can cleave specifically the bcr-abl RNA thereby blocking the synthesis of BCR-ABL protein, the primary cause of these leukemias.
  • the design of the hammerhead is such that it can only affect the oncogenic bcr-abl gene product without having any effect on normal ber and c-abl gene transcripts. By cleaving the bcr-abl gene transcript, this ribozyme can prohibit synthesis of the BCR-ABL protein associated with tumor cells and, return the cells to normalcy.
  • the hammerhead ribozyme which is preferred in this invention, comprises separate sequences: a catalytic sequence and a substrate binding sequence in two parts (the bcr-abl mRNA is the substrate) .
  • the ribozyme is a synthetic, catalytic RNA of between 35-45 nucleotides in length. A presently preferred ribozyme is about 40 nucleotides in length.
  • the designed ribozyme may vary in structure so long as it contains the catalytic sequence. However, the cleavage rates of the ribozyme will vary depending upon the secondary (and possibly tertiary) structures of the hammerhead.
  • the hammerhead ribozyme of this invention comprises a single strand of ribonucleic acids comprising: (1) a sequence complementary to a sequence of the coding strand of the hybrid gene 5 ⁇ to the breakpoint of the translocation and capable of hybridizing to that part of the gene (a first substrate binding sequence) ; (2) a second sequence complementary to a sequence of the coding strand of the hybrid gene 3' to the breakpoint of the translocation and capable of hybridizing thereto (a second substrate binding sequence) , and (3) a sequence therebetween encoding a catalytic ribozyme domain capable of cleaving the hybrid chromosome at or near the breakpoint (the catalytic or ribozyme sequence) .
  • Substrate binding sequences (1) and (2) above depend for their structure on the sequence of the hybrid gene which is targeted for destruction by the invention. These sequences are complementary to appropriate parts of the hybrid gene which flank the translocation breakpoint, e.g., the portion of the gene at which the two chromosomes are fused. The function of these sequences of the RNA molecule of this invention is to specifically isolate the hybrid gene RNA and position the ribozyme (3) for cleavage of the gene. These sequences (1) and (2) are desirably between 5 to 11 nucleotides in length. More preferably, these flanking sequences are between 6 and 10 nucleotides in length.
  • the length of these sequences provides a hybridization event with the target gene sufficient to permit cleavage of the gene at or near the breakpoint, thereby disabling the production of the hybrid tumorigenic protein.
  • the RNA molecule is designed to dissociate from the pieces. The ability to release the fragments of the cleaved gene relates alsp to the length of the flanking sequences of the RNA molecule. The same RNA molecule may then encounter another gene and perform the same cleavage function repeatedly until the molecule is eventually degraded by the cell.
  • a ribozyme molecule of this invention has a 40 nucleotide base sequence comprising substrate binding sequence catalytic sequence
  • the ribozyme may be provided with a cap structure, e.g. a 5'GpppG, which acts as a stabilizer in an intracellular environment.
  • a cap structure e.g. a 5'GpppG
  • the sequence of the RNA oncogene bcr-abl, i.e., the site on the bcr-abl gene transcript where the RNA molecule of this invention will bind is: 5 1 A-G-C-A-G-A-G-A- G-U-U (cleavage site)-C-A-A-A-A-G-C-C-U 3'.
  • the ribozyme is designed so that cleavage occurs after the 5' GUU 3' sequence of the bcr-abl mRNA.
  • Fig. 2 illustrates the binding of the ribozyme to the substrate (the bcr-abl gene transcript) .
  • the ribozyme of this invention can be prepared by chemical synthesis or produced in recombinant vectors by conventional means [see, T. Maniatis et al, Molecular Cloning (A Laboratory Manual) , Cold Spring Harbor Laboratory (1982)].
  • ribozyme RNA sequences may be synthesized conventionally by means of, for example, the RNA polymerase system such as T7 or SP6.
  • bcr-abl mRNA substrates may be cloned from, for example, K562 cell line (available from the American Type Culture Collection, Rockville, MD, USA, Accession Number ATCC# CCL 243) or BV173, EM2, Nalm-1,
  • the sequence of the bcr-abl gene is published in E. Shtivelman et al, Nature, 315:550-553 (1985) .
  • the RNAs are separated by electrophoresis and purified in acrylamide-urea gels.
  • the mechanism by which the ribozyme works is as follows: the substrate strand is designed in such a way that one half of it hybridizes to the ber sequence of the hybrid gene and the other half of the substrate RNA binds to the abl sequence of the hybrid gene.
  • the catalytic sequence is thereby placed in proximity to the 5•GUU3'sequence of the site of the targeted hybrid gene.
  • the bcr-abl gene transcript Upon cleavage the bcr-abl gene transcript is destroyed, and the ability of the gene to direct the synthesis of BCR-ABL protein is interrupted. In the absence of the oncogenic protein, the cell returns essentially to normal.
  • ribozyme effects only site-specific cleavage, normal cellular ber and abl gene transcript sites therefore remain unaffected by the action of the ribozyme. Thus, only cells containing the translocation resulting in the Philadelphia Chromosome are altered by this ribozyme.
  • recombinant vectors are employed for both production of the ribozyme of this invention and to provide delivery systems for exposing bone marrow cells to the ribozyme.
  • the ribozyme construct may be placed in a viral vector, of which many are known to the art. Viral vectors are preferred because they have the capacity to infect the cell where the ribozyme must be
  • vectors are retroviral vectors, adenoviral vectors, vaccinia vectors, and others, such as described by E. Gilboa, Adv. Exp. Med. Biol.. 241:29 (1988) and P.H. Pouwels et al, "Vectors for Animal Cells", in Cloning
  • lipid delivery system first described in P. L. Feigner et al, Proc. Natl. Acad. Sci. USA. 84:7413-7417 (1987).
  • the lipid functions to fuse with the cells allowing the ribozyme to enter the cells.
  • Transferrinfection of K562 cells recently shown to be an effective alternative to retroviral infection, may be successfully employed as a delivery system [Cotten et al, PNAS. 82:4033 (1990)].
  • Other delivery systems may include direct addition of the ribozyme to cells, which has been shown to be successful with antisense DNA oligomers [S. L. Luke et al, PNAS, 6:3474-3478 (1989)].
  • the ribozyme of the present invention may thus be employed as a therapeutic agent in the treatment of leukemias and other cancers such as those characterized by the presence of the Philadelphia Chromosome.
  • the method according to this invention may also be used in the treatment of other diseases, such as any leukemia or solid tumor which results from and contains the fusion of at least two normal genes, resulting in the generation of an abnormal chimeric gene product, or otherwise characterized by the presence of other chimeric gene products resulting from chromosomal translocations or other fusion mechanisms, wherein the resulting gene has a 5-GUX3 1 sequence close to the breakpoint.
  • Other ribozymes may be designed according to this method for use in analogous treatments for these other cancers.
  • this treatment is accomplished by contacting bone marrow cells extracted from a patient ex vivo with a sufficient number of ribozymes, or vectors carrying ribozymes, for a time sufficient to effect cleavage of the oncogene present in the cells.
  • the method may employ contacting the cells in vivo, for example, by administration directly into the bone marrow of a leukemic patient of vectors carrying the RNA molecule of the invention.
  • the RNA molecule of this invention causes the specific destruction of the bcr-abl mRNA, resulting in the loss of synthesis of the tumorigenic BCR-ABL protein.
  • the ribozyme Once transmitted into the cellular environment via a vector, the ribozyme is expected to survive within the cell for a short period of time. Since there is not necessarily only a one to one relationship between the ribozyme and the target oncogene, a single ribozyme is expected to bind and cleave a number of oncogenic transcripts before being degraded or destroyed by the natural enzymes in the cells and/or the natural functions of the immune system.
  • the patient may be treated with conventional chemotherapy or radiation to substantially destroy the remaining bone marrow cells carrying the bcr-abl oncogene, and the treated cells are then returned to the patient.
  • the treated cells when returned to the patient may then be stimulated by various known hematopoietic growth factors to repopulate the bone marrow with cells which do not carry the oncogenic transcript.
  • This method has the advantage over conventional cancer or leukemia treatments, such as bone marrow transplant, of avoiding complications caused by lack of compatibility and rejection because in the present method only the patient's own cells are involved. Further, it is expected that many of the side effects associated with conventional chemotherapy may be avoided because the treatment takes place essentially ex vivo. However, this method may also be used in connection with other treatments, such as radiation or chemotherapy.
  • the jLn vitro reaction depicted in Fig. 3 indicates the applicability of the reaction to the in vivo conditions.
  • the reaction was performed at 37°C under physiological pH of 7.5 with the presence of the Mg++ cofactor. Under these conditions enzymatic activity will occur until the elimination of either the substrate or degradation of the ribozyme.
  • the number of ribozymes which are required can be determined in vitro by titration of a known substrate with known riboxyme until no activity is observed.
  • the ribozyme was synthesized as an oligonucleotide on an Applied Biosystems DNA synthesizer.
  • the 40 mer ribozyme was purified by isolation from 20% polyacrylamide-7 M urea gels. The products are located by either autoradiography or UV shadowing. The resultant products band is crushed, and soaked for between 1 hour and overnight in 2 volumes of 0.5 M NaOAc pH 7.0. The extracted RNA is concentrated by ethanol precipitation and resuspended in H 2 0. Purified RNAs are stored in H 2 0 at -20°C.
  • the resulting ribozyme was 40 nucleotides in length with the following sequence: substrate binding sequence catalytic sequence
  • G-U-C-G-U-U-U-U-C-G-G-A 5• wherein U is Uridine, C is Cytosine, G is Guanidine, and A is Adenine.
  • bcr-abl RNA containing the bcr-abl breakpoint was expressed by inserting a 420 bp fragment of bcr-abl cDNA, which was constructed from a library constructed from K562 mRNA, into the plasmid vector pGEM5 (Promega) . This sequence is transcribed in vitro using T7 RNA polymerase in the presence of 32 P-rCTP. The resulting labelled RNA was isolated and purified.
  • the vector containing the BCR-ABL fragment was linearized by Nde I digestion and transcribed in vitro using T7 RNA polymerase in the presence of 32 P-rCTP. The reaction was stopped after one hour at 37°C by the addition of DNASE. Following digestion of the plasmid template, labelled RNA transcripts were loaded onto a 4% PAGE-7M urea gel and isolated by elution of the band from the gel slice. The purified RNA transcript was resuspended in H 2 0 and stored at -20°C until use.
  • the T7 polymerase generated RNA transcript was 499 bases in length; with 73 bases of pGEM 5 polylinker sequence prior to the 420 bases of BCR/ABL substrate and 6 bases from the polylinker restriction linearization site.
  • the GUU cleavage site is located 140 bases from the 5* end of the BCR/ABL specific sequences.
  • RNA transcript was used to characterize the cleavage products which would be expected if the assay described below in Example 3 proved the efficacy of the ribozyme.
  • an intact 499 nucleotide fragment extending from the T7 polymerase start site, to the end of the linearized plasmid. This includes the BCR/ABL segment as well as sequences from the pGEM5 expression plasmid. If cleavage of the bcr-abl RNA occurs, the 499 fragment is split into two fragments 213 and 286 nucleotides in length.
  • This RNA was used as a substrate in the test of Example 3 below.
  • the ribozyme of Example 1 was cleave the bcr-abl mRNA substrate.
  • the ribozyme of Example 1 and the RNA substrate of Example 2 (1 pmol of each) were mixed in a 10- ⁇ l reaction volume containing 50 mM Tris-HCl, pH 7.5. This resembles the physiologic pH of 7.4.
  • the MgCl 2 is omitted and 10 mM EDTA is added as the typical ribozyme-mediated cleavage is dependent on metal ions such as Mg++.
  • the mixture is heated to 95°C for 2 minutes and quick-cooled on ice. 10 mM MgCl 2 is added and then the mixture is incubated at 37°C for 14 hours.
  • the bcr-abl fragment sizes were 290 nucleotides and 160 nucleotides. [See lanes 5 and 6 in the gel of Fig. 3]. These results also show that the cleavage occurs very efficiently in the presence of Mg-H- ions. In contrast, this cleavage reaction was inhibited by EDTA. These results indicate that the introduction of this synthetic RNA ribozyme into leukemic cells synthesizing bcr-abl gene transcripts will result in the specific degradation of bcr-abl RNA which, in turn, prevents the synthesis of the oncogene BCR-ABL. Thus, this treatment is expected to result in the reversal of the leukemic process.
  • Example 4 Production and Use of a Vector for Delivery of the Ribozyme to Cells
  • the ribozyme is inserted as a DNA fragment into a retroviral expression vector.
  • a synthesized DNA fragment such that its expression will result in the active ribozyme molecule, is cloned into a retroviral vector by standard methods (T. Maniatis et al, cited above) .
  • the retroviral vector, pC-1 contains the Moloney murine leukemia virus LTRs and a selectable neo gene.
  • the crippled vector allows packaging and infection of the inserted gene.
  • the recombinant virus containing the ribozyme DNA sequence is transfected into a packaging cell-line, such as PA317 or 2, to generate a producer cell line.
  • Bone marrow cells from a leukemic patient are infected either by co-cultivation with the producer cell- line or by incubation with cell-free virus containing supernatant. Following overnite infection, the bone marrow cells are washed in PBS and grow in vitro for a period of 14-21 days. Successfully infected cells are selected for by the inclusion of G418 (Gibco) in the medium at two days post-infection. The presence of the neo gene in the ribozyme-containing retrovirus allows for growth in the presence of this compound. Therefore cells which were not infected die. The population of infected bone marrow cells are transplanted into the patient. Bone marrow cells and/or peripheral blood samples are monitored by the PCR-RT technique using BCR-ABL specific primers to show the presence or absence of BCR/ABL transcripts and the success of the treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouvelle ribozyme capable de cliver sélectivement l'ARN messager bcr-abl d'une cellule contenant le chromosome de Philadelphie, bloquant ainsi la synthèse de protéine BCR-ABL. L'invention concerne également des procédés d'utilisation de la ribozyme dans le traitement de patients leucémiques, ainsi que des procédés de production des ribozymes.
PCT/US1991/004545 1990-06-26 1991-06-25 Procede de traitement de leucemies WO1992000080A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP91912361A EP0639226A1 (fr) 1990-06-26 1991-06-25 Molecule d'arn pour utilisation dans le traitement de leucemies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54419990A 1990-06-26 1990-06-26
US544,199 1990-06-26

Publications (1)

Publication Number Publication Date
WO1992000080A1 true WO1992000080A1 (fr) 1992-01-09

Family

ID=24171171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004545 WO1992000080A1 (fr) 1990-06-26 1991-06-25 Procede de traitement de leucemies

Country Status (3)

Country Link
EP (1) EP0639226A1 (fr)
CA (1) CA2086105A1 (fr)
WO (1) WO1992000080A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551294A1 (fr) * 1991-08-01 1993-07-21 City Of Hope Inhibition par les ribozymes de l'expression du gene bcr-abl
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
WO1993023057A1 (fr) * 1992-05-14 1993-11-25 Ribozyme Pharmaceuticals, Inc. Procede et reactif destines a empecher l'evolution du cancer
WO1994013793A1 (fr) * 1992-12-04 1994-06-23 Apollon, Inc. Composes et methodes de traitement des leucemies
WO1995007923A1 (fr) * 1993-09-15 1995-03-23 Temple University Of The Commonwealth System Of Higher Education Inhibition de l'expression d'un oncogene par des ribozymes a unites multiples
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
US5610052A (en) * 1992-08-26 1997-03-11 Ribozyme Pharmaceuticals Inc. Enzymatic RNA with activity to ras
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US5639655A (en) * 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
WO1997018305A3 (fr) * 1995-11-14 1997-07-10 Univ Minnesota Procede pour preparer des cellules hematopoietiques non malignes pharmacoresistantes
US5658780A (en) * 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5811300A (en) * 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US6132967A (en) * 1992-12-07 2000-10-17 Ribozyme Pharmaceuticals, Inc. Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
US6492512B1 (en) 1992-08-26 2002-12-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
US6544755B1 (en) 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005852A1 (fr) * 1987-12-15 1989-06-29 Macphillamy Cummins & Gibson Ribozymes
US4874853A (en) * 1988-04-18 1989-10-17 City Of Hope Synthetic oligonucleotides useful in diagnosis of chronic myelogenous leukemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005852A1 (fr) * 1987-12-15 1989-06-29 Macphillamy Cummins & Gibson Ribozymes
US4874853A (en) * 1988-04-18 1989-10-17 City Of Hope Synthetic oligonucleotides useful in diagnosis of chronic myelogenous leukemia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FEBS Letters, Volume 239, No. 2, issued November 1988, M. KOIZUMI et al., "Cleavage of Specific Sites of RNA by Designed Ribozymes", pages 285-288, see entire document. *
Gene, Volume 82, issued 1989, D.E. RUFFMER et al., "Studies on the Hammerhead RNA Self-cleaning Domain", pages 31-41, see entire document. *
Nature, Volume 334, issued 18 August 1988, J. HASELOFF et al., "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities", pages 585-591, see entire document. *
Science, Volume 247, issued 09 March 1990, N. SARVER et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents", pages 1222-1225, see entire document. *
See also references of EP0639226A4 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
EP0551294A1 (fr) * 1991-08-01 1993-07-21 City Of Hope Inhibition par les ribozymes de l'expression du gene bcr-abl
EP0551294A4 (en) * 1991-08-01 1993-12-29 City Of Hope Ribozyme inhibition of bcr-abl gene expression
WO1993023057A1 (fr) * 1992-05-14 1993-11-25 Ribozyme Pharmaceuticals, Inc. Procede et reactif destines a empecher l'evolution du cancer
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
US5610052A (en) * 1992-08-26 1997-03-11 Ribozyme Pharmaceuticals Inc. Enzymatic RNA with activity to ras
US6544755B1 (en) 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene
US6492512B1 (en) 1992-08-26 2002-12-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
US5817796A (en) * 1992-08-26 1998-10-06 Stinchcomb; Dan T. C-myb ribozymes having 2'-5'-linked adenylate residues
US5801158A (en) * 1992-08-26 1998-09-01 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA with activity to RAS
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
WO1994013793A1 (fr) * 1992-12-04 1994-06-23 Apollon, Inc. Composes et methodes de traitement des leucemies
US6080851A (en) * 1992-12-04 2000-06-27 American Home Products Corporation Ribozymes with linked anchor sequences
US5811300A (en) * 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5658780A (en) * 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
US5731295A (en) * 1992-12-07 1998-03-24 Ribozyme Pharmaceuticals, Inc. Method of reducing stromelysin RNA via ribozymes
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US6132967A (en) * 1992-12-07 2000-10-17 Ribozyme Pharmaceuticals, Inc. Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
US6410224B1 (en) 1992-12-07 2002-06-25 Ribozyme Pharmaceuticals, Inc. Ribozyme treatment of diseases or conditions related to levels of NF-κB
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5639655A (en) * 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
WO1995007923A1 (fr) * 1993-09-15 1995-03-23 Temple University Of The Commonwealth System Of Higher Education Inhibition de l'expression d'un oncogene par des ribozymes a unites multiples
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
WO1997018305A3 (fr) * 1995-11-14 1997-07-10 Univ Minnesota Procede pour preparer des cellules hematopoietiques non malignes pharmacoresistantes

Also Published As

Publication number Publication date
EP0639226A4 (fr) 1993-11-11
CA2086105A1 (fr) 1991-12-27
EP0639226A1 (fr) 1995-02-22

Similar Documents

Publication Publication Date Title
US5246921A (en) Method for treating leukemias
EP0639226A1 (fr) Molecule d'arn pour utilisation dans le traitement de leucemies
JP3015463B2 (ja) 真核リボヌクレアーゼｐを用いるｒｎａの標的化切断および外部ガイド配列
EP0748383B1 (fr) Clivage cible de l'arn par ciblage de la ribonuclease p et sequences de clivage
US5869254A (en) Alteration of sequence of a target molecule by ribozyme catalyzed trans-splicing
US5750390A (en) Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
WO2002059300A2 (fr) Suppression de gene mediee par arn bicatenaire
US6573072B1 (en) Ribozymes having 2′-O substituted nucleotides in the flanking sequences
KR19980701418A (ko) 안정화된 외부 가이드 서열
CA2304813A1 (fr) Acides nucleiques catalyseurs a activite d'endonuclease
AU2013245555A1 (en) Antisense compounds targeted to connexins and methods of use thereof
US6916653B2 (en) Ribozymal nucleic acid
US5599704A (en) ErbB2/neu targeted ribozymes
EP1298208A2 (fr) Ribozymes contre une séquence de Tat de HIV
Usman et al. Design, synthesis, and function of therapeutic hammerhead ribozymes
US5622854A (en) Method and reagent for inhibiting T-cell leukemia virus replication
AU661124B2 (en) Enhancement of ribozyme catalytic activity by a neighboring facilitator oligonucleotide
JP2002509692A (ja) アンチセンスオリゴヌクレオチドによるヒト乳頭腫ウイルスの阻害
US7045293B2 (en) Alteration of sequence of a target molecule
US6544755B1 (en) Method and reagent for treatment of diseases by expression of the c-Myc gene
US6492512B1 (en) Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
Qiu Cellular ribonucleases and the design of hammerhead ribozymes
Chen Identification of optimal target sequences for antisense-, ribozyme-, and decoy-mediated gene inhibition
AU2002246742A1 (en) Double-stranded RNA-mediated gene suppression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991912361

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2086105

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991912361

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991912361

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载